Bronchiectasis Drugs Market to grow by USD 326.01 million from 2022 to 2027 | Increasing cases of associated risk factors to boost the market growth - Technavio

NEW YORK, July 7, 2023 /PRNewswire/ -- The global bronchiectasis drugs market size is estimated to grow by USD 326.01 million from 2022 to 2027, according to Technavio. The market is estimated to grow at a CAGR of 9.98% during the forecast period. North America is estimated to account for 44% of the global market growth. The market in North America is primarily driven by the sales of various off-label drug therapies approved for other chronic respiratory conditions and the increasing prevalence of chronic respiratory diseases and bronchiectasis. In addition, the use of antibiotics in combination with alternative treatment options, due to the absence of approved therapies, is expected to drive the bronchiectasis drugs market in the region during the forecast period. For more insights on the historic period (2017 to 2021) and forecast market size (2023 to 2027) - Request a sample report

What's New?

• Special coverage on the Russia-Ukraine war; global inflation; recovery analysis from COVID-19; supply chain disruptions, global trade tensions; and risk of recession 
• Global competitiveness and key competitor positions 
• Market presence across multiple geographical footprints - Strong/Active/Niche/Trivial - buy the report!

Bronchiectasis drugs market - Segmentation Assessment
Segment Overview
Technavio has segmented the market based on the product (antibiotics, expectorants, and others), distribution channel (offline and online), and geography (North America, Europe, Asia, and Rest of the World (ROW)). 

• The market share growth by the antibiotics segment will be significant for the market growth during the forecast period. The growth of the segment is driven by factors such as the low cost of drugs and their availability, affordability, and accessibility. Even though all the pathogens associated with the respiratory system resist various antibiotics, a single antibiotic cannot inhibit all the pathogens in and around the respiratory tract. Hence, various antibiotics are used in combination to achieve the desired clinical outcome. This increases the volume consumption of antibiotics, which drives the growth of the segment.

Insights on the market contribution of various segments, including country and region wise historic data (2017 to 2021), and forecast market size (2023 to 2027) - Download a Sample Report

Bronchiectasis drugs market – Market Dynamics
Key factor driving market growth
The increasing cases of associated risks drive the market growth. Bronchiectasis frequently happens as a result of health conditions such as humoral immunodeficiency, inflammatory bowel disease (Crohn's disease and ulcerative colitis), rheumatologic diseases (rheumatoid arthritis and Sjogren's disease), chronic obstructive pulmonary disease (COPD), cystic fibrosis. These diseases are of great concern globally. Furthermore, the increased prevalence of bronchiectasis globally is also a result of various external factors, including an increase in the number of patients with related diseases. Hence, such factors boost the market growth during the forecast period.

Leading trends influencing the market 

The growing awareness about bronchiectasis is an emerging bronchiectasis drugs market trend. This condition is often misunderstood as common cough and cold, as the symptoms of most respiratory tract infections are overlapped. Often, this results in underdiagnosing the infection, which reduces the use of treatment options and thus affects the growth of the market. Primary and secondary healthcare centers need to be better informed about it to increase awareness of this disease. Additionally, some companies regularly organize educational programs to inform healthcare professionals and patients of available therapeutic options for the treatment of bronchiectasis. Hence, such trends boost the market growth during the forecast period.

Major challenges hindering the market growth

The lack of approved drugs for bronchiectasis challenges the growth of the market. The treatment options for bronchiectasis usually include medications, CPT, the use of lung airway devices, oxygen therapy, and surgery. Bronchiectasis can happen due to various reasons, but a wide range of treatments is required in some cases. But there are no authorized products in the global bronchiectasis drug market at present. Patient adherence to treatment continues to decline as a result of resistance to antibiotics. Hence, such challenges impede market growth during the forecast period.

Insights on Market Drivers, Trends, & Challenges, historic period (2017 to 2021), and forecast period (2023 to 2027)- Request a sample report!

What are the key data covered in this bronchiectasis drugs market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the bronchiectasis drugs market between 2023 and 2027
• Precise estimation of the size of the bronchiectasis drugs market and its contribution to the market with a focus on the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the bronchiectasis drugs market across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of bronchiectasis drugs market vendors

Gain instant access to 17,000+ market research reports. 

Technavio's SUBSCRIPTION platform

Related Reports:

The bronchitis treatment market size is expected to increase by USD 1.12 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 4.76%. Furthermore, this report extensively covers bronchitis treatment market segmentation by drug class (antibiotics, anti inflammatory drugs, and bronchodilator) and geography (North America, Europe, Asia, and Rest of World (ROW)). The increasing prevalence of smoking is notably driving the bronchitis treatment market growth.

The chronic obstructive pulmonary disease drugs market is estimated to grow at a CAGR of 6.09% between 2022 and 2027. The chronic obstructive pulmonary disease drugs market size is forecast to increase by USD 6,654.49 million. This market report extensively covers market segmentation by product (combination therapy and monotherapy), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and geography (North America, Europe, Asia, and Rest of World (ROW)).The rising prevalence of COPD is notably driving the market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.3 Market size 2022 

• 3.4 Market outlook: Forecast for 2022-2027
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global bronchiectasis drugs market 2017 - 2021
• Exhibit 18: Historic Market Size – Data Table on global bronchiectasis drugs market 2017 - 2021 ($ million)

• 4.2 Product Segment Analysis 2017 - 2021
• Exhibit 19: Historic Market Size – Product Segment 2017 - 2021 ($ million)

• 4.3 Distribution Channel Segment Analysis 2017 - 2021
• Exhibit 20: Historic Market Size – Distribution Channel Segment 2017 - 2021 ($ million)

• 4.4 Geography Segment Analysis 2017 - 2021
• Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)

• 4.5 Country Segment Analysis 2017 - 2021
• Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary 
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

• 5.2 Bargaining power of buyers 
• Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 5.3 Bargaining power of suppliers 
• Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 5.4 Threat of new entrants 
• Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

• 5.5 Threat of substitutes 
• Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

• 5.6 Threat of rivalry 
• Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

• 5.7 Market condition 
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Product

• 6.1 Market segments 
• Exhibit 30: Chart on Product - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Product - Market share 2022-2027 (%)

• 6.2 Comparison by Product 
• Exhibit 32: Chart on Comparison by Product
• Exhibit 33: Data Table on Comparison by Product

• 6.3 Antibiotics - Market size and forecast 2022-2027
• Exhibit 34: Chart on Antibiotics - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Antibiotics - Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Antibiotics - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Antibiotics - Year-over-year growth 2022-2027 (%)

• 6.4 Expectorants - Market size and forecast 2022-2027
• Exhibit 38: Chart on Expectorants - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on Expectorants - Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on Expectorants - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Expectorants - Year-over-year growth 2022-2027 (%)

• 6.5 Others - Market size and forecast 2022-2027
• Exhibit 42: Chart on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 43: Data Table on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 44: Chart on Others - Year-over-year growth 2022-2027 (%)
• Exhibit 45: Data Table on Others - Year-over-year growth 2022-2027 (%)

• 6.6 Market opportunity by Product 
• Exhibit 46: Market opportunity by Product ($ million)
• Exhibit 47: Data Table on Market opportunity by Product ($ million)

7 Market Segmentation by Distribution Channel

• 7.1 Market segments 
• Exhibit 48: Chart on Distribution Channel - Market share 2022-2027 (%)
• Exhibit 49: Data Table on Distribution Channel - Market share 2022-2027 (%)

• 7.2 Comparison by Distribution Channel 
• Exhibit 50: Chart on Comparison by Distribution Channel
• Exhibit 51: Data Table on Comparison by Distribution Channel

• 7.3 Offline - Market size and forecast 2022-2027
• Exhibit 52: Chart on Offline - Market size and forecast 2022-2027 ($ million)
• Exhibit 53: Data Table on Offline - Market size and forecast 2022-2027 ($ million)
• Exhibit 54: Chart on Offline - Year-over-year growth 2022-2027 (%)
• Exhibit 55: Data Table on Offline - Year-over-year growth 2022-2027 (%)

• 7.4 Online - Market size and forecast 2022-2027
• Exhibit 56: Chart on Online - Market size and forecast 2022-2027 ($ million)
• Exhibit 57: Data Table on Online - Market size and forecast 2022-2027 ($ million)
• Exhibit 58: Chart on Online - Year-over-year growth 2022-2027 (%)
• Exhibit 59: Data Table on Online - Year-over-year growth 2022-2027 (%)

• 7.5 Market opportunity by Distribution Channel
• Exhibit 60: Market opportunity by Distribution Channel ($ million)
• Exhibit 61: Data Table on Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview 
• Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation 
• Exhibit 63: Chart on Market share by geography 2022-2027 (%)
• Exhibit 64: Data Table on Market share by geography 2022-2027 (%)

• 9.2 Geographic comparison 
• Exhibit 65: Chart on Geographic comparison
• Exhibit 66: Data Table on Geographic comparison

• 9.3 North America - Market size and forecast 2022-2027
• Exhibit 67: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 68: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 69: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 70: Data Table on North America - Year-over-year growth 2022-2027 (%)

• 9.4 Europe - Market size and forecast 2022-2027
• Exhibit 71: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 72: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 73: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 74: Data Table on Europe - Year-over-year growth 2022-2027 (%)

• 9.5 Asia - Market size and forecast 2022-2027 
• Exhibit 75: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 76: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 77: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 78: Data Table on Asia - Year-over-year growth 2022-2027 (%)

• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 
• Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

• 9.7 US - Market size and forecast 2022-2027
• Exhibit 83: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 84: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 85: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 86: Data Table on US - Year-over-year growth 2022-2027 (%)

• 9.8 Germany - Market size and forecast 2022-2027
• Exhibit 87: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 88: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 89: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 90: Data Table on Germany - Year-over-year growth 2022-2027 (%)

• 9.9 UK - Market size and forecast 2022-2027
• Exhibit 91: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 92: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 93: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 94: Data Table on UK - Year-over-year growth 2022-2027 (%)

• 9.10 China - Market size and forecast 2022-2027
• Exhibit 95: Chart on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 96: Data Table on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 97: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibit 98: Data Table on China - Year-over-year growth 2022-2027 (%)

• 9.11 Canada - Market size and forecast 2022-2027
• Exhibit 99: Chart on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 100: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 101: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibit 102: Data Table on Canada - Year-over-year growth 2022-2027 (%)

• 9.12 Market opportunity by geography 
• Exhibit 103: Market opportunity by geography ($ million)
• Exhibit 104: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers 

• 10.2 Market challenges 

• 10.3 Impact of drivers and challenges 
• Exhibit 105: Impact of drivers and challenges in 2022 and 2027

• 10.4 Market trends 

11 Vendor Landscape

• 11.1 Overview 

• 11.2 Vendor landscape 
• Exhibit 106: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption 
• Exhibit 107: Overview on factors of disruption

• 11.4 Industry risks 
• Exhibit 108: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered 
• Exhibit 109: Vendors covered

• 12.2 Market positioning of vendors 
• Exhibit 110: Matrix on vendor position and classification

• 12.3 AbbVie Inc. 
• Exhibit 111: AbbVie Inc. - Overview
• Exhibit 112: AbbVie Inc. - Product / Service
• Exhibit 113: AbbVie Inc. - Key news
• Exhibit 114: AbbVie Inc. - Key offerings

• 12.4 Akorn Operating Co LLC 
• Exhibit 115: Akorn Operating Co LLC - Overview
• Exhibit 116: Akorn Operating Co LLC - Product / Service
• Exhibit 117: Akorn Operating Co LLC - Key offerings

• 12.5 Amneal Pharmaceuticals Inc. 
• Exhibit 118: Amneal Pharmaceuticals Inc. - Overview
• Exhibit 119: Amneal Pharmaceuticals Inc. - Business segments
• Exhibit 120: Amneal Pharmaceuticals Inc. - Key news
• Exhibit 121: Amneal Pharmaceuticals Inc. - Key offerings
• Exhibit 122: Amneal Pharmaceuticals Inc. - Segment focus

• 12.6 Aurobindo Pharma Ltd. 
• Exhibit 123: Aurobindo Pharma Ltd. - Overview
• Exhibit 124: Aurobindo Pharma Ltd. - Product / Service
• Exhibit 125: Aurobindo Pharma Ltd. - Key offerings

• 12.7 Bayer AG 
• Exhibit 126: Bayer AG - Overview
• Exhibit 127: Bayer AG - Business segments
• Exhibit 128: Bayer AG - Key news
• Exhibit 129: Bayer AG - Key offerings
• Exhibit 130: Bayer AG - Segment focus

• 12.8 Boehringer Ingelheim International GmbH
• Exhibit 131: Boehringer Ingelheim International GmbH - Overview
• Exhibit 132: Boehringer Ingelheim International GmbH - Business segments
• Exhibit 133: Boehringer Ingelheim International GmbH - Key news
• Exhibit 134: Boehringer Ingelheim International GmbH - Key offerings
• Exhibit 135: Boehringer Ingelheim International GmbH - Segment focus

• 12.9 Dr Reddys Laboratories Ltd. 
• Exhibit 136: Dr Reddys Laboratories Ltd. - Overview
• Exhibit 137: Dr Reddys Laboratories Ltd. - Business segments
• Exhibit 138: Dr Reddys Laboratories Ltd. - Key offerings
• Exhibit 139: Dr Reddys Laboratories Ltd. - Segment focus

• 12.10 Endo International Plc 
• Exhibit 140: Endo International Plc - Overview
• Exhibit 141: Endo International Plc - Business segments
• Exhibit 142: Endo International Plc - Key news
• Exhibit 143: Endo International Plc - Key offerings
• Exhibit 144: Endo International Plc - Segment focus

• 12.11 GlaxoSmithKline Plc 
• Exhibit 145: GlaxoSmithKline Plc - Overview
• Exhibit 146: GlaxoSmithKline Plc - Business segments
• Exhibit 147: GlaxoSmithKline Plc - Key news
• Exhibit 148: GlaxoSmithKline Plc - Key offerings
• Exhibit 149: GlaxoSmithKline Plc - Segment focus

• 12.12 Hikma Pharmaceuticals Plc 
• Exhibit 150: Hikma Pharmaceuticals Plc - Overview
• Exhibit 151: Hikma Pharmaceuticals Plc - Business segments
• Exhibit 152: Hikma Pharmaceuticals Plc - Key offerings
• Exhibit 153: Hikma Pharmaceuticals Plc - Segment focus

• 12.13 Lupin Ltd. 
• Exhibit 154: Lupin Ltd. - Overview
• Exhibit 155: Lupin Ltd. - Product / Service
• Exhibit 156: Lupin Ltd. - Key news
• Exhibit 157: Lupin Ltd. - Key offerings

• 12.14 Neopharma Corp. 
• Exhibit 158: Neopharma Corp. - Overview
• Exhibit 159: Neopharma Corp. - Product / Service
• Exhibit 160: Neopharma Corp. - Key news
• Exhibit 161: Neopharma Corp. - Key offerings

• 12.15 Pfizer Inc. 
• Exhibit 162: Pfizer Inc. - Overview
• Exhibit 163: Pfizer Inc. - Product / Service
• Exhibit 164: Pfizer Inc. - Key news
• Exhibit 165: Pfizer Inc. - Key offerings

• 12.16 Reckitt Benckiser Group Plc 
• Exhibit 166: Reckitt Benckiser Group Plc - Overview
• Exhibit 167: Reckitt Benckiser Group Plc - Business segments
• Exhibit 168: Reckitt Benckiser Group Plc - Key offerings
• Exhibit 169: Reckitt Benckiser Group Plc - Segment focus

• 12.17 Viatris Inc. 
• Exhibit 170: Viatris Inc. - Overview
• Exhibit 171: Viatris Inc. - Business segments
• Exhibit 172: Viatris Inc. - Key news
• Exhibit 173: Viatris Inc. - Key offerings
• Exhibit 174: Viatris Inc. - Segment focus

13 Appendix

• 13.1 Scope of the report 

• 13.2 Inclusions and exclusions checklist
• Exhibit 175: Inclusions checklist
• Exhibit 176: Exclusions checklist

• 13.3 Currency conversion rates for US$ 
• Exhibit 177: Currency conversion rates for US$

• 13.4 Research methodology 
• Exhibit 178: Research methodology
• Exhibit 179: Validation techniques employed for market sizing
• Exhibit 180: Information sources

• 13.5 List of abbreviations 
• Exhibit 181: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com

SOURCE Technavio